PCSK9

From Proteopedia

proteopedia linkproteopedia link

Revision as of 12:39, 29 July 2019 (edit) Alexander Berchansky (Talk | contribs) ← Previous diff		Revision as of 10:13, 13 November 2019 (edit) (undo) Michal Harel (Talk | contribs) Next diff →
Line 24:		Line 24:
	[[3p5b]], [[3p5c]] – hPCSK9 + LDLR variant <br />		[[3p5b]], [[3p5c]] – hPCSK9 + LDLR variant <br />
	[[4ov6]] – hPCSK9 + adnectin <br />		[[4ov6]] – hPCSK9 + adnectin <br />
		+	[[6f5g]] – hPCSK9 C terminal + VHH minibody <br />
		+
	== References ==		== References ==
	<references/>		<references/>
	[[Category:Topic Page]]		[[Category:Topic Page]]

---

Revision as of 10:13, 13 November 2019

spinqualitylabelsall models Structure of human PCSK9 catalytic domain (blue) and prodomain (green) complex with LDL receptor EGF-A domain (magenta) and Ca+2 ion (PDB entry 2w2m) Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image Function PCSK9 or Proprotein Convertase Subtilisin/Kexin type 9 is a proteinase which is part of the cholesterol synthesis[1]. PCSK9 undergoes autocatalysis producing an active enzyme from its precursor. PCSK9 binds to EGF-A domain of the LDL receptor (LDLR) inducing its degradation. See details in Pro-protein convertase subtilisin/kexin type 9 (PCSK9). Relevance Low levels of LDL receptor are a cause of hypercholesterolemia since LDLR removes LDL cholesterol from the blood. Thus PCSK9 is an important drug target as its level affects the amount of cholesterol in blood[2]. Inhibition of PCSK9 results in increased pathogen lipid clearance, decreased inflammatory response and improved septic shock outcome[3]. Structural highlights . Water molecules are shown as red spheres. . .

3D structures of PCSK9

Updated on 13-November-2019

2p4e, 2pmw, 2qtw – hPCSK9 – human
3bps, 2w2m, 3gcx – hPCSK9 + LDLR EGF-A
2w2n, 3gcw – hPCSK9 + LDLR EGF-A (mutant)
2w2o, 2w2p, 2w2q – hPCSK9 (mutant) + LDLR EGF-A
3h42 – hPCSK9 (mutant) + antibody
2xtj, 3sqo, 4k8r – hPCSK9 + antibody
3m0c – hPCSK9 (mutant) + LDLR
3p5b, 3p5c – hPCSK9 + LDLR variant
4ov6 – hPCSK9 + adnectin
6f5g – hPCSK9 C terminal + VHH minibody

References

1. ↑ Piper DE, Jackson S, Liu Q, Romanow WG, Shetterly S, Thibault ST, Shan B, Walker NP. The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol. Structure. 2007 May;15(5):545-52. PMID:17502100 doi:http://dx.doi.org/10.1016/j.str.2007.04.004
2. ↑ Seidah NG. Proprotein convertase subtilisin kexin 9 (PCSK9) inhibitors in the treatment of hypercholesterolemia and other pathologies. Curr Pharm Des. 2013;19(17):3161-72. PMID:23317404
3. ↑ Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, Cirstea MS, Boyd JH. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Sci Transl Med. 2014 Oct 15;6(258):258ra143. doi: 10.1126/scitranslmed.3008782. PMID:25320235 doi:http://dx.doi.org/10.1126/scitranslmed.3008782